BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors

Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40–50% of cases are positive. To uncover other potential targetable mutations, we performed whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V559,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dahlman, Kimberly Brown, Xia, Junfeng, Hutchinson, Katherine, Ng, Charles, Hucks, Donald, Jia, Peilin, Atefi, Mohammad, Su, Zengliu, Branch, Suzanne, Lyle, Pamela L., Hicks, Donna J., Bozon, Viviana, Glaspy, John A., Rosen, Neal, Solit, David B., Netterville, James L., Vnencak-Jones, Cindy L., Sosman, Jeffrey A., Ribas, Antoni, Zhao, Zhongming, Pao, William
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3449158/
https://ncbi.nlm.nih.gov/pubmed/22798288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0097
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares